Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, the company and its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd. and Tianjin Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue the “Drug Clinical Trial Approval Notice” for HRS-4357 injections and HRS-5041 tablets, which will conduct clinical trials in the near future.

Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, the company and its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd. and Tianjin Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue the “Drug Clinical Trial Approval Notice” for HRS-4357 injections and HRS-5041 tablets, which will conduct clinical trials in the near future.